Evolus, Inc. (NASDAQ:EOLS) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Evolus a “Moderate Buy” consensus: Four of six analysts rate the stock a buy, while one rates it a hold and one a sell. The average 12-month price target is $14.50.
• Insider activity was negative: Insider David Moatazedi sold 105,108 shares for approximately $950,000, reducing his position by 17.38%; insiders own 5% of the company.
• Shares recently traded at $7.98, above the 50-day and 200-day moving averages of $7.51 and $6.34, respectively. Institutional investors and hedge funds hold 90.69% of EOLS stock.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.50.

EOLS has been the topic of a number of analyst reports. Wall Street Zen raised shares of Evolus from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. BTIG Research reaffirmed a "buy" rating and set a $13.00 price target on shares of Evolus in a research report on Wednesday, June 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Evolus in a report on Friday, September 11th. Finally, HC Wainwright reissued a "buy" rating and set a $13.00 target price on shares of Evolus in a research note on Tuesday, August 25th.

Insider Buying and Selling at Evolus

In related news, insider David Moatazedi sold 105,108 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the completion of the sale, the insider directly owned 499,592 shares of the company's stock, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.00% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of EOLS. Larson Financial Group LLC increased its position in shares of Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company's stock valued at $33,000 after acquiring an additional 2,837 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Evolus during the 2nd quarter worth approximately $40,000. Quantbot Technologies LP acquired a new stake in Evolus in the 2nd quarter valued at approximately $56,000. Sequoia Financial Advisors LLC acquired a new stake in Evolus in the 2nd quarter valued at approximately $71,000. Finally, WINTON GROUP Ltd purchased a new stake in Evolus in the second quarter valued at approximately $77,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Stock Performance

Shares of EOLS stock traded down $0.03 on Friday, hitting $7.98. 60,692 shares of the stock traded hands, compared to its average volume of 1,025,750. Evolus has a twelve month low of $3.86 and a twelve month high of $9.31. The firm's 50-day moving average price is $7.51 and its two-hundred day moving average price is $6.34. The stock has a market capitalization of $526.88 million, a PE ratio of -15.34 and a beta of 1.42.

About Evolus

Evolus, Inc is a medical aesthetics company focused on developing and commercializing products for healthcare professionals and consumers. The company's business is centered on aesthetic treatments designed to address facial lines, wrinkles, skin quality and other signs of aging.

Evolus' flagship product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved in the United States for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines.” The company markets Jeuveau through its physician-focused Evolus Aesthetic Center platform and related digital tools, education and patient-engagement services.

The company has expanded beyond neuromodulators into dermal fillers and other aesthetic products, including its Evolysse hyaluronic acid filler portfolio.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.